PharmAbcine-B (02617): Tingengetinib (TT-00420) is granted fast track designation for the treatment of MCRPC.

The China Finance app news, PharmaEngine-B (02617) announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for its drug tinengotinib (TT-00420) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients.